Abstract
ANA. All women on TAM and ANA reported to be 100% compliant by self report. After the controlling for prescriptions, only 40 (80%) and 29 (66%) of the women on TAM and ANA were still classified compliant (p < 0.0027 and p < 0.00055). We found no significant correlation of compliance in accordance to baseline characteristic and side effects in a log. regression model. Conclusions: An important goal of any therapeutic intervention is to achieve comparable efficacy in routine clinical practice to that demonstrated in RCTs. A similar magnitude in compliance in routine clinical practice will be necessary to assure comparable clinical effects. Our results further support the suboptimal compliance of women with breast cancer on adjuvant TAM treatment. Additionally, we for the first time evaluated an equivalent low compliance with ANA. More prospective studies are needed to increase our understanding of the underling reasons for non-compliance in women with breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
